160 related articles for article (PubMed ID: 29038319)
1. We need a "made in Canada" orphan drug framework.
McMillan HJ; Campbell C
CMAJ; 2017 Oct; 189(41):E1274-E1275. PubMed ID: 29038319
[No Abstract] [Full Text] [Related]
2. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
3. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
Roberts EA; Herder M; Hollis A
CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
[No Abstract] [Full Text] [Related]
4. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
5. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
6. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
7. Rare diseases and effective treatments: are we delivering?
Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
[No Abstract] [Full Text] [Related]
8. The balancing act of orphan drug pricing.
The Lancet
Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
[No Abstract] [Full Text] [Related]
9. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
10. An Orphan Drug Framework (ODF) for Canada.
Lee DK; Wong B
J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
[TBL] [Abstract][Full Text] [Related]
11. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.
Copley-Merriman K
Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343
[No Abstract] [Full Text] [Related]
12. Why we should care about ultra-rare disease.
Harari S
Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
[TBL] [Abstract][Full Text] [Related]
13. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
14. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
15. Rationing of drugs for rare diseases.
Hughes D
Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277
[No Abstract] [Full Text] [Related]
16. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
17. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
18. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
19. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
20. Canada's progress toward an orphan drug framework: 2014.
Lee DK
J Popul Ther Clin Pharmacol; 2014; 21(1):e41. PubMed ID: 24671825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
